Wearable Devices Ltd. current report, Q3 FY2022

Full document

Wearable Devices Ltd. — Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, dated September 22, 2022, covers the Company’s September 2022 activities. Wearable Devices Ltd. is an Israeli foreign private issuer that files annual reports on Form 20-F.

IPO and Key Financial Metrics

  • On September 15, 2022, the Company closed its initial public offering of 3,750,000 units.
  • Each unit included one ordinary share and two warrants, sold at $4.25 per unit.
  • The Company also sold warrants to purchase up to 1,125,000 ordinary shares under a partial exercise of the underwriters’ over-allotment option at $0.01 per warrant.
  • The IPO generated approximately $16 million of aggregate gross proceeds before underwriting discounts and offering expenses. Net proceeds were not provided in the filing.
  • The warrants have an exercise price of $4.00 per ordinary share and are exercisable immediately through September 15, 2027.
  • There is no revenue, profitability, cash flow, margin, debt, liquidity, or balance-sheet information in this filing.

Material Changes and Unusual Items

  • The Company completed its IPO and became publicly traded during the reporting period.
  • The ordinary shares and warrants began trading on the Nasdaq Capital Market on September 13, 2022 under the symbols WLDS and WLDSW, respectively.
  • Aegis Capital Corp. acted as sole book-running manager in a firm-commitment offering.

Guidance, Outlook, Risks, and Contingencies

The filing does not provide financial guidance, operating outlook, management forecasts, or a discussion of material risks beyond the terms and structure of the IPO and warrants. The offering proceeds are described only on a gross basis, and the filing does not state how the proceeds will be used.

Investor Verification Items

  • Verify the final net IPO proceeds after underwriting discounts and offering expenses.
  • Review the underwriting agreement and warrant form for dilution, redemption, exercise, and other terms.
  • Assess the potential dilution from the 7,500,000 warrants included with the units and the additional 1,125,000 warrants issued through the over-allotment option.
  • Review the Company’s subsequent Form 20-F and other filings for cash balances, operating results, use of proceeds, and liquidity.
  • Confirm the number of ordinary shares outstanding after the IPO and the potential impact of warrant exercises through September 15, 2027.